Contents

Reviews

Clinical Implications of High-mobility Group Box-1 (HMGB1) and the Receptor for Advanced Glycation End-products (RAGE) in Cutaneous Malignancy: A Systematic Review. A.H. NGUYEN, S.Q. DETTY, D.K. AGRAWAL (Omaha, NE, USA) ................................................................................................................................................................................................. 1

Parenchymal-sparing Hepatectomy as the New Doctrine in the Treatment of Liver-metastatic Colorectal Disease: Beyond Oncological Outcomes. D. MORIS, D. DIMITROULIS, S. VERNADAKIS, A. PAPALAMPROS, E. SPARTALIS, A. PETROU, T.M. PAWLIK, E. FELEKOURAS (Cleveland; Columbus, OH, USA; Athens, Greece) ............................................................................................................................................................................................................ 9

Three Pathways of Colonic Carcinogenesis in Rats. C.A. RUBIO (Stockholm, Sweden) .................................. 15

Advances in Experimental Targeted Therapy and Immunotherapy for Patients with Glioblastoma Multiforme. J. POLIVKA JR, J. POLIVKA, L. HOLUBEC, T. KUBIKOVA, V. PRIBAN, O. HES, K. PIVOVARCIKOVA, I. TRESKOVA (Plzen, Czech Republic) ............................................................................................................................................................................................... 21


Experimental Studies

KIF11 Is Required for Spheroid Formation by Oesophageal and Colorectal Cancer Cells. T. IMAI, N. OUE, K. SENTANI, N. SAKAMOTO, N. URAOKA, H. EGI, T. HINOI, H. OHDAN, K. YOSHIDA, W. YASUI (Hiroshima; Gifu; Kure, Japan) ................................................................................................................................. 47

Contents continued on the back cover
Editorial Board

P. A. Abrahamsson  
Department of Urology, Skåne University Hospital, Lund University, Malmö, Sweden

B. B. Aggarwal  
Cytokine Research Laboratory, Department of Experimental Therapeutics, University of Texas M.D. Anderson Cancer Center, Houston, TX, USA

T. Akimoto  
Division of Particle Therapy and Department of Radiation Oncology, National Cancer Center East, Kashiwa, Chiba, Japan

P. Z. Anastasiadis  
Department of Cancer Biology, Mayo Cancer Center, Jacksonville, FL, USA

A. Argris  
Division of Hematology/Oncology, UT Health Science Center at San Antonio, San Antonio, TX, USA

J. P. Armand  
Institut Claudius Regaud, Toulouse, France

V. I. Avramis  
Division of Hematology/Oncology, Childrens Hospital, Los Angeles, CA, USA

D.-T. Bau  
Terry Fox Cancer Research Lab, China Medical University Hospital, Taichung, Taiwan, ROC

G. Bauer  
Abteilung Virologie, Institut für Medizinische Mikrobiologie und Hygiene, Universität Freiburg, Germany

E. E. Baulieu  
INSERM U488 and College de France, Le Kremlin-Bicêtre, France

E. J. Benz, Jr.  
Dana-Farber Cancer Institute, Boston, MA, USA

J. Bergh  
Department of Clinical and Molecular Medicine, Radiumhemmet, Karolinska Institute, Stockholm, Sweden

F. T. Bosman  
Institute of Pathology, University of Lausanne, Switzerland

M. Bouvet  
Department of Surgery, University of California San Diego, Moores Cancer Center, La Jolla, CA, USA

J. Boyd  
Department of Human and Molecular Genetics, Herbert Wertheim College of Medicine, Florida International University, Miami, FL, USA

G. Broich  
Gruppo Policlinico di Monza, Monza, Italy

Ø. S. Bruland  
Department of Medical Oncology-Radiotherapy, Norwegian Radium Hospital, Oslo, Norway

J. M. Buatti  
Department of Radiation Oncology, University of Iowa, Iowa City, IA, USA

M. M. Burger  
Novartis, Basel, Switzerland

M. Carbone  
Cancer Research Center of Hawaii, Honolulu, HI, USA

C. Carlberg  
Institute of Biomedicine, University of Eastern Finland, Kuopio, Finland

J. Carlsson  
Department of Biomedical Radiation Sciences, Uppsala University, Sweden

A. F. Chambers  
Department of Oncology, London Regional Cancer Center, London, Ontario, Canada

P. Chandra  
Abt. für Molekularbiologie, Klinikum Wolfgang Goethe-Universität, Frankfurt am Main, Germany

L. Cheng  
Department of Pathology, Indiana University School of Medicine, Indianapolis, IN, USA

J.-G. Chung  
Department of Biological Science and Technology, China Medical University, Taichung, Taiwan, ROC

R. Clarke  
Georgetown University Medical Center, Washington, DC, USA

E. De Clercq  
Rega Institute for Medical Research, Katholieke Universiteit Leuven, Belgium

W. Den Otter  
VUMC, Department of Urology, Amsterdam, The Netherlands

E. P. Diamandis  
Department of Pathology and Laboratory Medicine, Mount Sinai Hospital, Toronto, Ontario, Canada

G. Th. Diamandopoulos  
Department of Pathology, Harvard Medical School, Boston, MA, USA

D. W. Felsher  
Division of Oncology, Stanford University School of Medicine, Stanford, CA, USA

J. A. Fernandez-Pol  
Metalloproteomics, LLC, Chesterfield, MO, USA

I. J. Fidler  
Department of Cancer Biology, University of Texas M.D. Anderson Cancer Center, Houston, TX, USA

A. P. Fields  
Department of Cancer Biology, College of Medicine, Mayo Clinic, Jacksonville, FL, USA

H. Fu  
Discovery and Developmental Therapeutics Program of Winship Cancer Institute, Emory University, Atlanta, GA, USA

B. Fuchs  
Balgrist University Hospital, Zurich, Switzerland

D. Fuchs  
Center for Chemistry and Biomedicine, Innsbruck Medical University, Innsbruck, Austria

G. Gabbiani  
Department of Pathology, University of Geneva, Switzerland

continued
Acknowledgements

The IIAR appreciates the support of the following Foundations, Institutions, Organizations and Universities for the works published in Anticancer Research, Volume 36, 2016.

A.P. Moeller Foundation, Copenhagen, Denmark
Academic Scholarship, Seoul National University College of Medicine Alumni Association, Port Washington, NY, U.S.A.
Academy of Finland, Helsinki, Finland
Advanced Research Foundation Inc., New Rochelle, NY, U.S.A.
Albert Hung Foundation, Hong Kong, P.R. China
Algeria’s General Directorate for Scientific Research and Technological Development (DGRSDT), Algiers, Algeria
Alliance Pour la Recherche En Cancérologie (APREC), Paris, France
Alma Toorock Memorial for Cancer Research, Brooklyn, NY, U.S.A.
American Association of Cancer Researchers, Philadelphia, PA, U.S.A.
American Cancer Society, Atlanta, GA, U.S.A.
American Chemical Society (ACS), Washington, DC, U.S.A.
American Heart Association, Dallas, TX, U.S.A.
American Journal Experts (AJE), Durham, NC, U.S.A.
Asa Norte Regional Hospital (HRAN), Brasília, Brazil
Asahi Kasei Pharma Corp., Tokyo, Japan
Asan Institute for Life Sciences, Asan Medical Center, Seoul, Republic of Korea
Assistance Publique des Hôpitaux de Paris (APHP), Paris, France
Austrian Science Fund (FWF), Vienna, Austria
Avtal om Läkarutbildning och Forskning (ALF), Lund University and Region Skane, Lund, Sweden
Basic Science Research Program, National Research Foundation of Korea (NRF), Ministry of Education, Science and Technology, Seoul, Republic of Korea
Bavarian State Ministry of the Environment and Consumer Protection, Munich, Germany
Bayer HealthCare Pharmaceuticals, Montville, NJ, U.S.A.
Becket-Fonden, Copenhagen, Denmark
Beijing Municipal Science & Technology Commission, Beijing, P.R. China
Benson Idahosa University, Benin City, Nigeria
Beppu Medical Center, Beppu, Japan
Berlin Institute of Health, Berlin, Germany
Bettina Bräu Foundation, Munich, Germany
Bio and Medical Technology Department Program, National Research Foundation (NRF), Ministry of Education, Science and Technology, Seoul, Republic of Korea
Biobanking and BioMolecular resources Research Infrastructure (BBMRI), Austria
Bio-oriented Technology Research Advancement Institution, National Agriculture and Food Research Organization (NARO), Tsubuka, Japan
Bioscience Group and Head, Radiation Biology & Health Sciences Division (BARC), Mumbai, India
Biozoom Services GmbH, Kassel, Germany
Bone and Soft-Tissue Clinic, Peter McCallum Cancer Institute, Melbourne, VIC, Australia
Bonner Forschung (BONFOR) Research Grant, University Medical Center, University of Bonn, Bonn, Germany
Boston University School of Medicine (BUSM), Boston, MA, U.S.A.
Brain Tumour Foundation of Canada, London, ON, Canada
Breast Cancer Research Foundation, New York, NY, U.S.A.
California State University Dominguez Hills, Carson, CA, U.S.A.
Canadian Breast Cancer Foundation, Canada
Canadian Tumour Repository Network, Canada
Cancer and Allergy Foundation, Gothenburg, Sweden
Cancer Care West-Hardiman Scholarship, Galway, Ireland
Cancer Registry, Hannover Medical School, Hannover, Germany
Cancer Research Foundation Norrland, Umeå, Sweden
Cancer Research Society, Ottawa, ON, Canada
Cancer Research Wales, Wales, U.K.
Cancer Society, Stockholm, Sweden
Cancéropôle Grand Ouest, Lille, France
Capacity Development Award, Canadian Cancer Society, Canada
Cardiff China Medical Research Collaborative, Cardiff University, Wales, U.K.
Cardiff University’s China Medical Scholarship, Cardiff University, Wales, U.K.
Catholic Medical Center Research Foundation, Seoul, Republic of Korea
David Geffen School of Medicine at UCLA, Los Angeles, CA, U.S.A.
Deanship of Scientific Research (DSR), King Abdulaziz University, Jeddah, Kingdom of Saudi Arabia
Dell’Angelo Hospital Mestre-Venice, Venice, Italy
Department of Clinical Research Center, Wakayama Medical University, Wakayama, Japan
Department of Comprehensive Clinical Oncology, Faculty of Medical Sciences, Kyushu University, Fukuoka, Japan
Department of Environmental, Biological and Pharmaceutical Sciences and Technologies, Second University of Naples, Caserta, Italy
Department of Gastroenterological Surgery and Urology, Osaka University, Osaka, Japan
Department of Gastroenterology and Hepatology, Osaka University, Osaka, Japan
Department of Health, Biotechnology Research Program, Commonwealth of Pennsylvania, U.S.A.
Department of Histology and Embryology, Wroclaw Medical University, Wroclaw, Poland
Department of Integrative medicine, Osaka University, Osaka, Japan
Department of International Medical Communications, Tokyo Medical University, Tokyo, Japan
Department of Medical Sciences, The Graduate School, Ajou University, Suwon, Republic of Korea
Department of Medicine and Biosystemic Science, Graduate School of Medical Sciences, Kyushu University, Fukuoka City, Japan
Department of Medicine, University of Wisconsin, Madison, WI, U.S.A.
Department of Molecular Pharmacology and Oncology, Gunma University Graduate School of Medicine, Gunma, Japan
Department of Nuclear Medicine, Taichung Tzu Chi Hospital, Taichung, Taiwan, R.O.C.
Department of Obstetrics and Gynecology, University of Tübingen, Tübingen, Germany
Department of Oncology, University Hospital of Ioannina, Ioannina, Greece
Department of Ophthalmology, University Medical Center Hamburg-Eppendorf (UKE), Hamburg, Germany
Department of Oral Pathology, Institute of Pathology, Universitätsklinik Hamburg-Eppendorf, Hamburg, Germany
Department of Orthopaedics, St. Vincent’s Hospital Melbourne, Fitzroy, VIC, Australia
Department of Pathology and Laboratory Medicine Service, Minneapolis VA Medical Center, Minneapolis, MN, U.S.A.
Department of Pathology, Radiumhospitalet, Oslo University Hospital, Oslo, Norway
Department of Radiation Oncology, Gunma University, Maebashi, Japan
Department of Science and Technology, Guangxi Province, P.R. China
Department of Veterans Affairs, Washington, DC, U.S.A.
Departments of Surgical Pathology, Library, Medical Media and Research Services, Minneapolis VA Medical Center, Minneapolis, MN, U.S.A.
Departments of Urology, Radiology and Radiation Oncology, Osaka Medical College, Takatsuki, Japan
Dermal Toxicology and Effects Group, Centre for Radiation, Chemical and Environmental Hazards, Public Health England, U.K.
Des Moines University, Des Moines, IA, U.S.A.
Desna Robins Jones Charitable Trust, Bridgend, U.K.
Deutsche Forschungsgemeinschaft (DFG), Bonn, Germany
Deutsche Krebshilfe, Bonn, Germany
DexTech Medical AB, Uppsala, Sweden
Diversity Grant, National Institute of Radiological Sciences (NIRS)-Chiba University, Japan
Division of Gastroenterology and Hepatology, University of Wisconsin, Madison, WI, U.S.A.
Dynamic Science S.L., Barcelona, Spain
Edanz, Fukuoka, Japan
Editage, Tokyo, Japan
Eisai GmbH, Frankfurt, Germany
Eli Lilly and Company, Indianapolis, IN, U.S.A.
Else og Mogens Wedell-Wedellsborgs Fond, Skodsborg, Denmark
Enrico and Enrica Sovena Foundation, Italy
European Institute of Oncology, Milan, Italy
European Regional Development Fund (ERDF), Brussels, Belgium
European Social Fund (ESF), European Commission, Brussels, Belgium
European Structural and Investment Funds, European Commission, Brussels, Belgium
EuroTransBio (ETB), Seventh Framework Programme, European Commission, Brussels, Belgium
Experimental Pathology, University of Wisconsin Carbone Cancer Center, Madison, WI, U.S.A.
Ez Communications, Matsumoto, Japan
F. Hoffmann-La Roche AG, Basel, Switzerland
Fabrikant Einer Willumsens Mindelegat, Copenhagen, Denmark
Fabrikant Willumsens Mindelegat, Copenhagen, Denmark
Faculté des Sciences Pharmaceutiques et Biologiques, Université Paris Descartes, Paris, France
Faculty Hospital in Pilsen (FNPl), Pilsen, Czech Republic
Faculty of Medicine in Pilsen, Charles University in Prague, Pilsen, Czech Republic
Faculty of Medicine Publication Clinic, Khon Kaen University, Khon Kaen, Thailand
Faculty of Pharmaceutical Sciences, Chulalongkorn University, Bangkok, Thailand
Fellowships of Excellence for Postgraduate Studies in Greece-Siemens Program, State Scholarships Foundation (IKY), Athens, Greece
Finnish Anti-tuberculosis Association, Helsinki, Finland
Finnish Cancer Society, Helsinki, Finland
Finnish Dental Society Apollonia, Helsinki, Finland
Finnish Medical Foundation, Helsinki, Finland
Finnish Medical Society Duodecim, Helsinki, Finland
Finnish Society For Oncology, Helsinki, Finland
Flint Animal Cancer Center, Colorado State University, Fort Collins, CO, U.S.A.
Fondation des Hôpitaux Enfant-Jésus – St-Sacrement (HEJ-SS), Ville de Québec, QC, Canada
Fondation du Cancer du Sein du Québec, Ville de Québec, QC, Canada
Fondation pour la Recherche Médicale (FRM), Paris, France
Fondazione Comunità Bresciana Onlus, Brescia, Italy
Fondazione Guido Berlucchi per la Ricerca sul Cancro Onlus, Borgonato, Italy
Fonds de recherche du Québec - Santé (FRQS), Montréal, QC, Canada
Förderung für Forschung und Lehre, LMU University, Munich, Germany
Forschungsförderung Ruhr-Universität Bochum Medizinischen Fakultät (FoRUM) Grant, Ruhr-University Bochum, Bochum, Germany
Foundation for Polish Science, Warsaw, Poland
Foundation for Promotion of Cancer Research, Tokyo, Japan
Foundation of Beijing Educational Committee, Beijing, P.R. China
Foundation of Skin Physiology, Donors’ Association for the Promotion of Sciences and Humanities in Germany, Germany
French Ministry of Health as part of Friedrich-Baur Foundation, Munich, Germany
Frits, Georg og Marie Gluds Legat, Aarhus, Denmark
Fukuoka Higashi Medical Center, Koga, Japan
Fund for Scientific Research – Flanders (FWO - Vlaanderen), Brussels, Belgium
Fundação Araucária do Paraná, Curitiba, PR, Brazil
Fundação para a Ciência e e Tecnologia (FCT), Ministério da Ciência e Ensino Superior, Portugal
Fundamental Research Grant, South University of Science and Technology of China, Shenzhen, P.R. China
Funding for Excellent Departments, Qingdao University, Qingdao, P.R. China
Fundo Estadual para a Infância e Adolescência (FIA/PR), Curitiba, PR, Brazil
Galenus-med GmbH, Frankfurt am Main, Germany
Galway University Foundation, Galway, Ireland
Gänseblümchen-Voerde Foundation, Voerde, Germany
Gazdaságfejlesztési és Innovációs Operatív Program (GINOP), Hungary
GE Healthcare, Chigaco, Il, U.S.A.
Genomics and Proteomics Core Laboratory, Department of Medical Research, Kaohsiung Chang Gung Memorial Hospital, Kaohsiung, Taiwan, R.O.C.
German Academic Exchange Program (DAAD), New York, NY, U.S.A.
German Federal Ministry of Education and Research (BMBF), Germany
German Institute of Human Nutrition, Nuthetal, Germany
Gesellschaft für KinderKrebsForschung e.V., Geltendorf, Germany
Global Robotics Institute, Florida Hospital, Orlando, FL, U.S.A.
Golfer’s Against Cancer Grant, Kingwood, TX, U.S.A.
Gout Research Foundation, Tokyo, Japan
Grant-in-Aid for Clinical Cancer Research, Ministry of Health, Labor and Welfare, Tokyo, Japan
Grant-in-Aid for Exploratory Research, Ministry of Education, Culture, Sports, Science and Technology (MEXT), Tokyo, Japan
Grant-in-Aid for Graduate Students, Hyogo College of Medicine, Nishinomiya, Japan
Grant-in-Aid for Scientific Research, Ministry of Health, Labor and Welfare of Japan, Tokyo, Japan
Grants-in Aid for Cancer Research: Research on HTLV-1 Associated Diseases, Saga Prefecture, Japan
Grants-in Aid for Cancer Research: Special Cancer Research, Ministry of Education, Science, Sports and Culture, Tokyo, Japan
Grants-in-Aid for Scientific Research (KAKENHI), Japan
Society for the Promotion of Science, Tokyo, Japan
Gujarat Council on Science and Technology, Gujarat, India
Gujarat State Biotechnology Mission, Gujarat, India
Gunnar Nilssons Cancerstiftelse, Helsingborg, Sweden
Hans-Sauer-Stiftung, Oberhaching, Germany
Harvard Medical School, Boston, MA, U.S.A.
Health and Welfare Data Science Center (HWDC), Taipei, Taiwan, R.O.C.
Health Labour Sciences Research Grant, Ministry of Health
Labour and Welfare, Tokyo, Japan
Health Research Board, Dublin, Ireland
Heavy Ion Medical Accelerator in Chiba (HIMAC), Chiba, Japan
Henry M. Jackson Foundation for the Advancement of
Military Medicine, Bethesda, MD, U.S.A.
Heriot Watt University (HWU), Edinburgh, Scotland, U.K.
Higher Education Commission of Pakistan (FAM), Islamabad, Pakistan
Higher Education Research Promotion, Bangkok, Thailand
Hiroshima Red Cross Hospital & Atomic Bomb Survivors
Hospital, Hiroshima, Japan
Hoffmann-La Roche Pharmaceuticals, Basel, Switzerland
Hokkaido University, Sapporo, Japan
Hospital Pharmacy, Fondazione IRCCS Policlinico San Matteo, Pavia, Italy
Hubei Key Laboratory of Stem Cell Research, Taihe Hospital, Hubei University of Medicine, Shiyan, P.R. China
Hubei Science and Technology Foundation, Shiyan, P.R. China
Hyogo Medical Center, Akashi, Japan
Hyogo Prefecture Health Promotion Association, Nishinomiya, Japan
Icahn School of Medicine at Mount Sinai, New York, NY, U.S.A.
Ichiro Kanehara Foundation, Japan
Iizuka Hospital, Fukuoka, Japan
Imperial Life Sciences (P) Limited, Gurugram, India
Incubating Program for Clinical Research and Innovation,
Renji Hospital Affiliated to Shanghai Jiao Tong University School of Medicine, Shanghai, P.R. China
Indian Council for Medical Research, New Delhi, India
Innovative Economy Operational Program, National
Strategic Reference Framework Program, European Union, Brussels, Belgium
Innovative Economy Operational Program, Provincial
Specialized Hospital, Research and Development Center, Wroclaw, Poland
Innovative Social Policies for Inclusive and Resilient
Labour Markets in Europe (INsPiRE), Seventh Framework Programme, European Commission, Brussels, Belgium
Inoue Enryou Memorial Foundation, Toyo University, Tokyo, Japan
Institut Curie, Paris, France
Institut National de la Santé et de la Recherche Médicale, France
Institute of Biomathematics, Faculty of Medicine, Mannheim, Germany
Institute of Bioorganic Chemistry Core Facility (CKP IBCH), Moscow, Russian Federation
Institute of Dentistry, University of Turku, Turku, Finland
Institute of Health Biosciences, University of Tokushima, Tokushima, Japan
Institute of Lighting Technics, Technical University Berlin, Berlin, Germany
Instituto de Medicina Molecular, Faculdade de Medicina de Lisboa, Lisbon, Portugal
Internal Grant Agency (IGA), Ministry of Health, Prague, Czech Republic
International Comparisons of Product Supply Chains in the Agro-food Sectors (COMPETE), Seventh Framework Programme, European Commission, Brussels, Belgium
IPSEN Pharma GmbH, Ettlingen, Germany
Ireland Alumni Student Research Programme, Royal College of Surgeons, Dublin, Ireland
Irish Cancer Society, Dublin, Ireland
Italian Association for Cancer Research (Associazione Italiana per la Ricerca sul Cancro, AIRC), Italy
Ithoh-Chubei Foundation, Japan
James and Esther King Florida Biomedical Research Program, Florida Department of Health, Tallahassee, FL, U.S.A.
János Bolyai Research Scholarship, Hungarian Academy of Sciences, Budapest, Hungary
Japan Agency for Medical Research and Development (AMED), Tokyo, Japan
Japan Foundation for Applied Enzymology (JFAE), Osaka, Japan
Japan Science and Technology Agency (JST), Kawaguchi, Japan
Japan Society for the Promotion of Science (JSPS), Tokyo, Japan
Laboratory for Process Engineering, Environment, Biotechnology and Energy (LEPABE), Faculty of Engineering of Porto (FEUP), Porto, Portugal
Laval University Cancer Research Center, Laval, QC, Canada
Lega Italiana Per La Lotta Contro i Tumori (LILT), Naples, Italy
Les Amis de Bordet, Brussels, Belgium
Life Sciences Research Network Wales, Wales, U.K.
Lifelong Learning Programme (LLP) Erasmus Programme, European Union
London Regional Cancer Program, London, U.K.
Louise Stokes Alliances for Minority Participation (LSAMP)
National Science Foundation Grant, Arlington, VA, U.S.A.
Ludwig-Maximilians-University (LMU), Munich, Germany
M.D. Anderson Cancer Center, Houston, TX, U.S.A.
MacArthur Foundation, Chicago, IL, U.S.A.
Magnetic Resonance Imaging Center, Hamburg, Germany
Mama Mare Breast Cancer Foundation, Easton, PA, U.S.A.
Manchester Metropolitan University, Manchester, U.K.
Marienhospital Stuttgart, Stuttgart, Germany
Masaryk Memorial Cancer Institute, Brno, Czech Republic
Max og Inger Wørzners Mindelegat, Denmark
Media Service, Minneapolis Veterans Affairs Medical Center, University of Minnesota, Minneapolis, MN, U.S.A.
Medical Prognosis Institute, Hørsholm, Denmark
Medical Research Core Facilities Center, Office of Research & Development, China medical University, Taichung, Taiwan, R.O.C.
Medical School, University of Ioannina, Ioannina, Greece
Medical University of Gdańsk, Gdańsk, Poland
Medical-Engineering Joint Fund, Shanghai Jiao Tong University, Minhang Qu, P.R. China
Medi-Kelsey Ltd, Ashbourne, U.K.
Meikai University School of Dentistry, Urayasu, Japan
Memorial Sloan Kettering Cancer Center, Department of Pathology, New York, NY, U.S.A.
Ministry of Agriculture, Forestry and Fisheries, Tokyo, Japan
Ministry of Economics and Science of the Saarland, Germany
Ministry of Education Youth and Sports, Prague, Czech Republic
Ministry of Education, Culture, Sports, Science and Technology (MEXT), Tokyo, Japan
Ministry of Education, Science and Technology, Seoul, Republic of Korea
Ministry of Health & Welfare, Sejong City, Republic of Korea
Ministry of Health and Welfare, Executive Yuan, Taipei, Taiwan, R.O.C.
Ministry of Health, Labor and Welfare, Tokyo, Japan
Ministry of Health, Prague, Czech Republic
Ministry of Science and Higher Education, Warsaw, Poland
Ministry of Science and Technology, Taipei, Taiwan, R.O.C.
Ministry of Science and Technology, Taipei, Taiwan, R.O.C.
Ministry of Science, Education and Sports (MZOS), Zagreb, Republic of Croatia
Ministry of Science, ICT & Future Planning (MSIP), Gwacheon, Republic of Korea
Molecular-Genetics Laboratory, Department of Hematology and Oncology, Faculty Hospital Pilsen, Pilsen, Czech Republic
Mrs. Berta Kamprad Foundation, Sweden
Münchener Medizinische Wochenschrift (MMW), Germany
MVZ Labor Limbach Berlin GbR, Berlin, Germany
Nagasaki University Graduate School of Biomedical Science, Nagasaki, Japan
Nagoya City University Graduate School of Medical Sciences, Nagoya, Japan
Nakatomi Foundation, Tokyo, Japan
Nakatsu Municipal Hospital, Nakatsu, Japan
Nambour Skin Cancer Study, Nambour, QLD, Australia
Nanotechnology Innovation Center Kansas State (NICKS), Manhattan, KS, U.S.A.
National Agency for Scientific Research (NASR), Tripoli, Libya
National Cancer Center Research and Development Fund, Japan
National Cancer Database (NCDB), Chicago, IL, U.S.A.
National Cancer Institute, National Institutes of Health, Bethesda, MD, U.S.A.
National Center for Research Resources, NIH, Bethesda, MD, U.S.A.
National Institute for General Medical Sciences (NIGMS), Bethesda, MD, U.S.A.
National Institute of Allergy and Infectious Diseases (NIAID), NIH, Bethesda, MD, U.S.A.
National Institute of Minority Health and Health Disparities (NIMHD), NIH, Bethesda, MD, U.S.A.
National Institute of Radiological Sciences (NIRS), Chiba, Japan
National Institute on Aging, Bethesda, MD, U.S.A.
National Institutes of Health, Department of Health and Human Services, Bethesda, MD, U.S.A.
National Kyushu Cancer Center, Japan
National Natural Science Foundation of China, Guangdong, P.R. China
National Natural Science Foundation of Zhejiang Province, Zhejiang, P.R. China
National Plan for Science, Technology and Innovation (MAARIFAH), Riyadh, Kingdom of Saudi Arabia
National R&D Program, Korea Institute of Radiological and Medical Sciences, Ministry of Science, ICT & Future Planning (MSIP), Gwacheon, Republic of Korea
National Research Council, Khartoum, Sudan
National Research Foundation of Korea (NRF), Ministry of Education, Science and Technology, Seoul, Republic of Korea
National Research Network Wales, Wales, U.K.
National Research Program in Biomedicine, Latvia
National Science Centre (NCN), Krakow, Poland
National Science Council of Taiwan, Taipei, Taiwan, R.O.C.
National Science Foundation (NSF), Arlington, VA, U.S.A.
National Science Fund of Bulgaria, Sofia, Bulgaria
National Sustainability Program I (NPU I), Ministry of Education Youth and Sports, Prague, Czech Republic
Natural Science Foundation of Shandong Province, Shandong, P.R. China
Natural Science Foundation, Jiangsu Science and Technology Department, Jiangsu, P.R. China
Neurofibromatosis Outpatient Center, Department of Neurology, Universitätshospital Hamburg-Eppendorf (UKE), Hamburg, Germany
NHO Kochi Hospital, Kochi, Japan
NIH Intramural Research Program, Bethesda, MD, U.S.A.
Nikon Instruments, Minneapolis, MN, U.S.A.
Nine Fields of Occupational Injuries and Illnesses, Ministry of Health, Labour, and Welfare, Tokyo, Japan
Nippon Suisan Kaisha, Ltd., Tokyo, Japan
Northumbria University (NNU), Newcastle upon Tyne, U.K.
Norwegian Institute of Public Health (NIPH), Oslo, Norway
Norwegian Radium Hospital Research Foundation, Oslo, Norway
Novartis Pharmaceuticals Corporation, New York, NY, U.S.A.
School of Medicine, Ajou University, Suwon, Republic of Korea
Schulich School of Medicine and Dentistry, London, ON, Canada
Science and Technology Unit, King Abdulaziz University, Jeddah, Kingdom of Saudi Arabia
Scientific Grant Agency, Ministry of Education, Science, Research and Sport, Bratislava, Slovak Republic
Screening Core Facility, National Centre for Biomedical Engineering Science (NCBES), Galway, Ireland
Secretaria da Ciência, Tecnologia e Ensino Superior (SETI), Curitiba, PR, Brazil
Secretaria da Família e Desenvolvimento Social (SEDS), Curitiba, PR, Brazil
Seoul National University Hospital (SNUH) Research Fund, Seoul, Republic of Korea
Shandong Province Young and Middle-aged Scientists Research Award of China, P.R. China
Shanghai Fund for Young Physician Development, Shanghai, P.R. China
Shanghai Pujiang Program, Shanghai, P.R. China
Shared Resource Support Grant, University of Colorado Cancer Center, Denver, CO, U.S.A.
Shenzhen Municipal Research Funds, Shenzhen, Hong Kong, P.R. China
Shin-Nakama Hospital, Nakama, Japan
Shizuoka Cancer Center Hospital, Shizuoka, Japan
Show Chwan Memorial Hospital, Changhua, Taiwan, R.O.C.
Sint Antonius Hospital, Nieuwegein, the Netherlands
Slovak Research and Development Agency (SRDA), Bratislava, Slovak Republic
Smoking Research Foundation (SRF), Tokyo, Japan
Social Insurance Nakabaru Hospital, Kasuya, Japan
Sonja Wasowicz Stiftung zur Förderung der Medizinischen Forschung, Essen, Germany
Soonchunhyang University Research Fund, Asan, Republic of Korea
South-Eastern Norway Regional Health Authority, Hamar, Norway
Specialization Project Research Grant, Pusan National University, Busan, Republic of Korea
Specific Health Problem in Greater Mekong Sub-region (SHeP-GMS), Health Cluster, National Research University Project of Thailand, Thailand's Office of the Higher Education Commission (OHEC), Bangkok, Thailand
Spogaards Family Fund, Denmark
Stanford University, Stanford, CA, U.S.A.

Stanley Tessis Fund, Toronto, ON, Canada
Startup Funds, Ministry of Education (MOE), Beijing, P.R. China
Steel Memorial Yahata Hospital, Kitakyushu, Japan
Stockholm Cancer Society, Stockholm, Sweden
Stockholm City Council, Stockholm, Sweden
Study of the Health Effects of Radiation, Ministry of the Environment, Tokyo, Japan
Supercomputer System, Human Genome Center, Institute of Medical Science, University of Tokyo, Tokyo, Japan
Supported Programs for the Strategic Research Foundations at Private Universities, MEXT, Japan
Swedish Breast Cancer Association (Bröstcancerföreningenarnas Riksorganisation, BRO), Stockholm, Sweden
Swedish Cancer Foundation, Stockholm, Sweden
Swedish Cancer Society, Stockholm, Sweden
Szeged Foundation for Cancer Research (Szegedi Rákkutatásért Alapítvány), Szeged, Hungary
Tagawa Municipal Hospital, Tagawa, Japan
Taiichung Armed Forces General Hospital, Taichung, Taiwan, R.O.C.
Taiichung Tzu Chi Hospital, Taichung, Taiwan, R.O.C.
Taiho Pharmaceutical Co. Ltd., Tokyo, Japan
Taiwan Academy Sinica Thematic Project, Taiwann, R.O.C.
Takeda Chemical Industries
Takeda Science Foundation, Japan
Taoyuan General Hospital, Ministry of Health and Welfare, Taoyuan City, Taiwan R.O.C.
Társadalmi Megújulás Operatív Program (TÁMOP), Hungary
Thailand Research Fund, Bangkok, Thailand
Thelma Mäkikyrö Foundation, Sweden
Thuréus foundation, Uppsala, Sweden
Tissue Bank, China Medical University, Taichung, Taiwan R.O.C.
Translational Research Informatics (TRI) Center, Kobe, Japan
TRF Senior Research Grant, Thailand Research Fund, Bangkok, Thailand
TriStar Technology Group, Rockville, MD, U.S.A.
Tsukuba University, Ibaraki, Japan
Turku University, Turku, Finland
Uehara Memorial Foundation, Tokyo, Japan
Umea University, Umea, Sweden
Undergraduate Research Opportunities Program (UROP), Boston University, Boston, MA, U.S.A.
Unit of Molecular Therapies, Department of Experimental Oncology and Molecular Medicine, Fondazione IRCCS Istituto Nazionale dei Tumori, Milan, Italy
Unité de Nutrition Humaine UMR 1019 INRA-UdA-Equipe ECREIN, St Genès Champanelle, France
University of Aberdeen, Aberdeen, Scotland, U.K.
University of Aveiro, Aveiro, Portugal
University of Brescia, Brescia, Italy
University of Helsinki, Helsinki, Finland
University of Maryland, College Park, MD, U.S.A.
University of Michigan, Ann Arbor, MI, U.S.A.
University of Minnesota, Minneapolis, MN, U.S.A.
University of Pécs, Pécs, Hungary
University of Salford, Salford, U.K.
University of South Florida (USF) Research Foundation, Tampa, FL, U.S.A.
University of Southern Denmark, Odense, Denmark
University of Tübingen, Tübingen, Germany
University of Wisconsin Carbone Cancer Center, Madison, WI, U.S.A.
University of Wisconsin, Madison, WI, U.S.A.
UV-Technik, Hanau, Germany
Vanderbilt University School of Medicine, Nashville, TN, U.S.A.
Vasterbotten County Council (ALF), Umea, Sweden
Victor Babes University of Medicine and Pharmacy, Timisoara, Romania
Wake Forest University, Winston-Salem, NC, U.S.A.
Walter Reed National Military Medical Center, Bethesda, MD, U.S.A.
Wellcome Trust, London, U.K.
West Virginia IDeA Network of Biomedical Research Excellence, West Virginia, U.S.A.
Wroclaw Medical University, Wroclaw, Poland
Wrovasc – Integrated Cardiovascular Centre, Wroclaw, Poland
Yantai Science and Technology Program, Yantai University, Yantai, P.R. China
Yantai Yuhuangding Hospital Initiative Foundation for Young, Yantai University, Yantai, P.R. China
Yen Tjing Ling Medical Foundation, Taiwan, R.O.C.
Instructions for Authors 2017

General Policy. ANTICANCER RESEARCH (AR) will accept original high quality works and reviews on all aspects of experimental and clinical cancer research. The Editorial Policy suggests that priority will be given to papers advancing the understanding of cancer causation, and to papers applying the results of basic research to cancer diagnosis, prognosis, and therapy. AR will also accept the following for publication: (a) Abstracts and Proceedings of scientific meetings on cancer, following consideration and approval by the Editorial Board; (b) Announcements of meetings related to cancer research; (c) Short reviews (of approximately 120 words) and announcements of newly received books and journals related to cancer, and (d) Announcements of awards and prizes.

The principal aim of AR is to provide prompt publication (print and online) for original works of high quality, generally within 1-2 months from final acceptance. Manuscripts will be accepted on the understanding that they report original unpublished works in the field of cancer research that are not under consideration for publication by another journal, and that they will not be published again in the same form. All authors should sign a submission letter confirming the approval of their article contents. All material submitted to AR will be subject to peer-review, when appropriate, by two members of the Editorial Board and by one suitable outside referee. All manuscripts submitted to AR are urgently treated with absolute confidence, with access restricted to the Managing Editor, the journal’s secretary, the reviewers and the printers. The Editors reserve the right to improve manuscripts on grammar and style.

The Editors and Publishers of AR accept no responsibility for the contents and opinions expressed by the contributors. Authors should warrant due diligence in the creation and issuance of their work.

NIH Open Access Policy. The journal acknowledges that authors of NIH-funded research retain the right to provide a copy of the published manuscript to the NIH four months after publication in ANTICANCER RESEARCH, for public archiving in PubMed Central.

Copyright. Once a manuscript has been published in ANTICANCER RESEARCH, which is a copyrighted publication, the legal ownership of all published parts of the paper has been transferred from the Author(s) to the journal. Material published in the journal may not be reproduced or published elsewhere without the written consent of the Managing Editor or Publisher.

Format. Two types of papers may be submitted: (i) Full papers containing completed original work, and (ii) review articles concerning fields of recognisable progress. Papers should contain all essential data in order to make the presentation clear. Reasonable economy should be exercised with respect to the number of tables and illustrations used. Papers should be written in clear, concise English. Spelling should follow that given in the “Shorter Oxford English Dictionary”.

Manuscripts. Submitted manuscripts should not exceed fourteen (14) pages (approximately 250 words per double-spaced typed page), including abstract, text, tables, figures, and references (corresponding to 4 printed pages). Papers exceeding 4 printed pages will be subject to excess page charges. All manuscripts should be divided into the following sections: (a) First page including the title of the presented work [not exceeding fifteen (15) words], full names and full postal addresses of all Authors, name of the Author to whom proofs are to be sent, key words, an abbreviated running title, an indication “review”, “clinical”, “epidemiological”, or “experimental” study, and the date of submission. (Note: The order of the Authors is not necessarily indicative of their contribution to the work. Authors may note their individual contribution(s) in the appropriate section(s) of the presented work); (b) Abstract not exceeding 150 words, organized according to the following headings: Background/Aim – Materials and Methods/Patients and Methods – Results – Conclusion; (c) Introduction; (d) Materials and Methods/Patients and Methods; (e) Results; (f) Discussion; (g) Acknowledgements; (h) References. All pages must be numbered consecutively. Footnotes should be avoided. Review articles may follow a different style according to the subject matter and the Author’s opinion. Review articles should not exceed 35 pages (approximately 250 words per double-spaced typed page) including all tables, figures, and references.

Figures. All figures should appear at the end of the submitted document file. Once a manuscript is accepted all figures and graphs should be submitted separately in either jpg, tif or pdf format and at a minimum resolution of 300 dpi. Graphs must be submitted as pictures made from drawings and must not require any artwork, typesetting, or size modifications. Symbols, numbering and lettering should be clearly legible. The number and top of each figure must be indicated. Pages that include color figures are subject to color charges.

Tables. All tables should appear at the end of the submitted document file. Once a manuscript is accepted, each table should be submitted separately, typed double-spaced. Tables should be numbered with Roman numerals and should include a short title.


Clinical Trials. Authors of manuscripts describing clinical trial should provide the appropriate clinical trial number in the correct format in the text.

For International Standard Randomised Controlled Trials (ISRCTN) Registry (a not-for-profit organization whose registry is administered by Current Controlled Trials Ltd.) the unique number must be provided in this format: ISRCTNXXXXXXXX (where XXXXXXXXX represents the unique number, always prefixed by “ISRCTN”). Please note that there is no space between the prefix “ISRCTN” and the number. Example: ISRCTN47956475.

For Clinicaltrials.gov registered trials, the unique number must be provided in this format: NCTXXXXXXXX (where XXXXXXXXX represents the unique number, always prefixed by ‘NCT’). Please note that there is no space between the prefix ‘NCT’ and the number. Example: NCT00001789.

Ethical Policies and Standards. ANTICANCER RESEARCH agrees with and follows the “Uniform Requirements for Manuscripts Submitted to Biomedical Journals” established by the International Committee of Medical Journal Editors in 1978 and updated in October 2001 (www.icmje.org). Microarray data analysis should comply with the “Minimum Information About Microarray Experiments (MIAME) standard”. Specific guidelines are provided at the “Microarray Gene Expression Data Society” (MGED) website. Presentation of genome sequences should follow the guidelines of the NHGRI Policy on Release of Human Genomic Sequence Data. Research involving human beings must adhere to the principles of the Declaration of Helsinki and Title 45, U.S. Code of Federal Regulations, Part 46, Protection of Human Subjects, effective December 13, 2001. Research involving animals must adhere to the Guiding Principles in the Care and Use of Animals approved by the Council of the American Physiological Society. The use of animals in biomedical research should be under the careful supervision of a person adequately trained in this field and the animals must be treated humanely at all times. Research involving the use of human foetuses, foetal tissue, embryos and embryonic cells should adhere to the U.S. Public Law 103-41, effective December 13, 2001.

Submission of Manuscripts. Please follow the Instructions for Authors regarding the format of your manuscript and references. Manuscripts must be submitted only through our online submission system at: http://www.iiar-submissions.com/login.html In case a submission is incomplete, the corresponding Author will be notified accordingly. Questions regarding difficulties in using the online submission system should be addressed to: email: journals@iiar-anticancer.org

Galley Proofs. Unless otherwise indicated, galley proofs will be sent to the corresponding Author of the submission. Corrections of galley proofs should be limited to typographical errors. Reprints, PDF files, and/or Open Access may be ordered after the acceptance of the paper. Authors of online open access articles are entitled to a complimentary online subscription to Anticancer Research for the current year and all previous digital content since 2004. Requests should be addressed to the Editorial Office. Galley proofs should be returned corrected to the Editorial Office by email within two days.

Specific information and additional instructions for Authors

1. Anticancer Research (AR) closely follows the new developments in all fields of experimental and clinical cancer research by (a) inviting reviews on topics of immediate importance and substantial progress in the last three years, and (b) providing the highest priority for rapid publication to manuscripts presenting original results judged to be of exceptional value. Theoretical papers will only be considered and accepted if they bear a significant impact or formulate existing knowledge for the benefit of research progress.

2. Anticancer Research will consider the publication of conference proceedings and/or abstracts provided that the material submitted fulfils the quality requirements and instructions of the journal, following the regular review process by two suitable referees.

3. An acknowledgement of receipt, including the article number, title and date of receipt is sent to the corresponding author of each manuscript upon receipt. If this receipt is not received within 20 days from submission, the author should call or write to the Editorial Office to ensure that the manuscript (or the receipt) was not lost in the mail or during electronic submission.

4. Each manuscript submitted to AR is sent for review in confidence to two suitable referees with the request to return the manuscript with their comments to the Editorial Office within 12 days from receipt. If reviewers need a longer time or wish to send the manuscript to another expert, the manuscript may be returned to the Editorial Office with a delay. All manuscripts submitted to AR are treated in confidence, without access to any person other than the Managing Editor, the journal’s secretary, the reviewers and the printers.
All accepted manuscripts are peer-reviewed and carefully corrected in style and language, if necessary, to make presentation clear. (There is no fee for this service). Every effort is made (a) to maintain the personal style of the author’s writing and (b) to avoid change of meaning. Authors will be requested to examine carefully manuscripts which have undergone language correction at the pre-proof or proof stage.

Authors should pay attention to the following points when writing an article for AR:

- The Instructions to Authors must be followed in every detail.
- The presentation of the experimental methods should be clear and complete in every detail facilitating reproducibility by other scientists.
- The presentation of results should be simple and straightforward in style. Results and discussion should not be combined into one section, unless the paper is short.
- Results given in figures should not be repeated in tables.
- Figures (graphs or photographs) should be prepared at a width of 8 or 17 cm with legible numbers and lettering.
- Photographs should be clear with high contrast, presenting the actual observation described in the legend and in the text. Each legend should provide a complete description, being self-explanatory, including technique of preparation, information about the specimen and magnification.
- Statistical analysis should be elaborated wherever it is necessary. Simplification of presentation by giving only numerical or % values should be avoided.
- Fidelity of the techniques and reproducibility of the results, should be points of particular importance in the discussion section. Authors are advised to check the correctness of their methods and results carefully before writing an article. Probable or dubious explanations should be avoided.
- Authors should not cite results submitted for publication in the reference section. Such results may be described briefly in the text with a note in parenthesis (submitted for publication by... authors, year).
- The References section should provide as complete a coverage of the literature as possible including all the relevant works published up to the time of submission.
- By following these instructions, Authors will facilitate a more rapid review and processing of their manuscripts and will provide the readers with concise and useful papers.

Following review and acceptance, a manuscript is examined in language and style, and galley proofs are rapidly prepared. Second proofs are not sent unless required.

Authors should correct their galley proofs very carefully and preferably twice. An additional correction by a colleague always proves to be useful. Particular attention should be paid to chemical formulas, mathematical equations, symbols, medical nomenclature etc. Any system of correction marks can be used in a clear manner, preferably with a red pen. Additions or clarifications are allowed provided that they improve the presentation but do not bring new results (no fee).

Articles submitted to AR may be rejected without review if:

- they do not fall within the journal's policy.
- they do not follow the instructions for authors.
- language is unclear.
- results are not sufficient to support a final conclusion.
- results are not objectively based on valid experiments.
- they repeat results already published by the same or other authors before the submission to AR.
- plagiarism is detected by plagiarism screening services.

(Rejection rate (2016): 66%).

Authors who wish to prepare a review should contact the Managing Editor of the journal in order to get confirmation of interest in the particular topic of the review. The expression of interest by the Managing Editor does not necessarily imply acceptance of the review by the journal.

Authors may inquire information about the status of their manuscript(s) by calling the Editorial Office at +30-22950-53389, Monday to Friday 9.00-16.00 (Athens time), or by sending an e-mail to journals@iiar-anticancer.org

Authors who wish to edit a special issue on a particular topic should contact the Managing Editor.

Authors, Editors and Publishers of books are welcome to submit their books for immediate review in AR. There is no fee for this service.

(Copyright© 2017 - International Institute of Anticancer Research (G.J. Delineasios). All rights reserved (including those of translation into other languages). No part of this journal may be reproduced, stored in a retrieval system, or transmitted in any form or by any means, electronic, mechanical, photocopying, microfilming, recording or otherwise, without written permission from the Publisher.)
Reviews